Takahiro Aoki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takahiro Aoki has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Katsuyoshi Koh
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
4 shared publicationsMakiko Mori
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
3 shared publicationsRyoji Hanada
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
3 shared publicationsYuki Arakawa
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
2 shared publicationsKosuke Akiyama
Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan
1 shared publicationMayumi Hayashi
1 shared publication
Latest Publications
- Open Access
- 1 September 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (9) , 1725-1728
Addition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review
- 1 September 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (9) , 1725-1728
Open AccessAddition of High-Dose Cytarabine to Fludarabine-Based Conditioning for Hematopoietic Stem Cell Transplantation for Treating Fanconi Anemia Patients with Advanced Myeloid Malignancy: A Single-Center Experience and Literature Review
- Open Access
- 1 April 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (4) , 771-775
Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
- 1 April 2016
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 22 (4) , 771-775
Open AccessSafety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
- 1 November 2014
- Vol. 55 (11) , 2316-9
Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia.
Clofarabine, one of the key treatment agents for refractory and relapsed acute lymphoblastic leukemia (ALL), achieves a remission rate of approximately 30% with single-agent clofarabine induction chemotherapy. However, a remission rate of approximately 50% was reported with a combination chemotherapy regimen consisting of clofarabine, etoposide, and cyclophosphamide. We treated two cases with refractory and relapsed ALL with combination chemotherapy including clofarabine; one was an induction failure but the other achieved remission. Both cases developed an infectious complication (NCI-CTCAE grade 3) and body pain with infusion. Prophylactic antibiotic and opioid infusions facilitated avoiding septic shock and pain. Further investigation of such cases is required.
- 1 November 2014
- Vol. 55 (11) , 2316-9
Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia.
Clofarabine, one of the key treatment agents for refractory and relapsed acute lymphoblastic leukemia (ALL), achieves a remission rate of approximately 30% with single-agent clofarabine induction chemotherapy. However, a remission rate of approximately 50% was reported with a combination chemotherapy regimen consisting of clofarabine, etoposide, and cyclophosphamide. We treated two cases with refractory and relapsed ALL with combination chemotherapy including clofarabine; one was an induction failure but the other achieved remission. Both cases developed an infectious complication (NCI-CTCAE grade 3) and body pain with infusion. Prophylactic antibiotic and opioid infusions facilitated avoiding septic shock and pain. Further investigation of such cases is required.
- 1 July 2014
- Vol. 55 (7) , 802-7
[Live vaccines in hematopoietic stem cell transplant recipients].